Protection Analysis

Panacea community - Protection sales by quarter

Product Q2 Q3 Q4 Q1 Total
Crit. Illness £1,338,384 £1,299,753 £3,851,564 £4,266,217 £10,755,919
Decreasing Term with CI £4,232,474 £4,249,517 £3,736,307 £3,279,683 £15,497,982
Income Prot. £3,282,948 £3,403,813 £5,328,514 £3,660,524 £15,675,798
Mortgage Term £8,309,348 £8,208,415 £7,853,251 £7,083,659 £31,454,673
Relevant Life £2,379,562 £2,159,192 £2,310,187 £2,321,212 £9,170,152
Term £19,129,615 £18,403,564 £17,584,278 £17,733,986 £72,851,443
Term with Critical Illness £6,138,303 £5,554,436 £5,718,771 £6,240,387 £23,651,898
Whole of Life £5,151,383 £5,696,947 £4,362,999 £4,463,733 £19,675,062
Grand total £49,962,018 £48,975,636 £50,745,873 £49,049,401 £198,732,929

 

Q2 18 to Q1 19 total Protection sales

Product Non-user Sales (£) Panacea Community Sales (£) TOTAL Market Share
Crit. Illness £20,379,879 £10,755,919 £31,135,798 35%
Decreasing Term with CI £37,735,117 £15,497,982 £53,233,099 29%
Income Prot. £29,805,787 £15,675,798 £45,481,585 34%
Mortgage Term £72,757,605 £31,454,673 £104,212,278 30%
Relevant Life £9,702,401 £9,170,152 £18,872,553 49%
Term £153,986,287 £72,851,443 £226,837,730 32%
Term with Critical Illness £58,348,803 £23,651,898 £82,000,700 29%
Whole of Life £23,725,111 £19,675,062 £43,400,174 45%
Grand total £406,440,989 £198,732,929 £605,173,918 33%

 

Please contact sarahpaul@panaceaadviser.com if you are interested in speaking to us further.

Email this article Print Share on Twitter Share on LinkedIn Share on Facebook Share on Google+